Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Ordinary Shares, nominal value EUR0.12 per share
-
Shares outstanding
-
113,609,919
-
Total 13F shares
-
33,346,896
-
Share change
-
-169,940
-
Total reported value
-
$444,858,187
-
Price per share
-
$13.26
-
Number of holders
-
19
-
Value change
-
+$689,119
-
Number of buys
-
12
-
Number of sells
-
3
Institutional Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS) as of Q1 2023
As of 31 Mar 2023,
NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,346,896 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Medicxi Ventures Management (Jersey) Ltd, BVF INC/IL, GMT CAPITAL CORP, Ensign Peak Advisors, Inc, and Parkman Healthcare Partners LLC.
This page lists
19
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.